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Background
The European Cancer Registry-based project on hematologic malignancies (HAEMACARE), set
up to improve the availability and standardization of data on hematologic malignancies in
Europe, used the European Cancer Registry-based project on survival and care of cancer
patients (EUROCARE-4) database to produce a new grouping of hematologic neoplasms
(defined by the International Classification of Diseases for Oncology, Third Edition and the
2001/2008 World Health Organization classifications) for epidemiological and public health
purposes. We analyzed survival for lymphoid neoplasms in Europe by disease group, compar-
ing survival between different European regions by age and sex. 
Design and Methods
Incident neoplasms recorded between 1995 to 2002 in 48 population-based cancer registries in
20 countries participating in EUROCARE-4 were analyzed. The period approach was used to
estimate 5-year relative survival rates for patients diagnosed in 2000-2002, who did not have 5
years of follow up. 
Results
The 5-year relative survival rate was 57% overall but varied markedly between the defined
groups. Variation in survival within the groups was relatively limited across European regions
and less than in previous years. Survival differences between men and women were small. The
relative survival for patients with all lymphoid neoplasms decreased substantially after the age
of 50. The proportion of ‘not otherwise specified’ diagnoses increased with advancing age. 
Conclusions
This is the first study to analyze survival of patients with lymphoid neoplasms, divided into
groups characterized by similar epidemiological and clinical characteristics, providing a bench-
mark for more detailed analyses. This Europe-wide study suggests that previously noted differ-
ences in survival between regions have tended to decrease. The survival of patients with all
neoplasms decreased markedly with age, while the proportion of ‘not otherwise specified’
diagnoses increased with advancing age. Thus the quality of diagnostic work-up and care
decreased with age, suggesting that older patients may not be receiving optimal treatment.
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Introduction 
Lymphoid neoplasms are a heterogeneous group of
hematologic malignancies that include non-Hodgkin’s
lymphoma (NHL), Hodgkin’s lymphoma (HL), plasma cell
neoplasms and lymphoid leukemias.1,2 Various classifica-
tions of these diseases, based mainly on morphological
and clinical criteria,3-6 were used in the past, but these
were superseded by the Revised European-American
Lymphoma (REAL) classification of 19947 which included
immunophenotypic and genotypic, as well as morpholog-
ical and clinical, criteria. The World Health Organization
(WHO) introduced a new classification in 2001. This was
based on the REAL classification but gained broader con-
sensus and, together with the revised WHO classification
of 2008,8 is now widely used by clinicians and patholo-
gists.9,10 The WHO terminology was incorporated into the
International Classification of Diseases for Oncology,
Third Edition (ICD-O-3)11 which uses all available criteria
to distinguish the various entities of lymphoid neoplasms
according to cell lineage and level of differentiation.1
Since the ICD-O-3 has been adopted by most European
population-based cancer registries it has now become pos-
sible, for the first time, to analyze the survival of patients
with lymphoid neoplasms in Europe using an internation-
ally recognized disease classification system. Nevertheless
major difficulties remain: it is not possible to analyze each
disease entity (defined by ICD-O-3 code) separately; there
are too many such entities and many of them are rare, so
even casting the net across most of Europe would not pro-
duce enough cases to enable a robust survival analysis. To
address this difficulty, hematologists, pathologists and epi-
demiologists from several European countries convened
under the aegis of a European Cancer Registry-based proj-
ect on hematologic malignancies (HAEMACARE) to pro-
duce a consensus grouping of lymphoid neoplasms (as
defined by ICD-O-3 morphology codes and WHO recom-
mendations) into sub-categories based primarily on cell
lineage with similar prognosis, of use for clinical and epi-
demiological studies. The HAEMACARE project made
use of data provided by cancer registries participating in
EUROCARE-4.12,13
The HAEMACARE lymphoid neoplasm grouping sys-
tem incorporates the changes introduced by the 2001 and
2008 WHO classifications1,8 and is consistent with the clas-
sification of lymphoid neoplasms for epidemiological
research proposed by the Pathology Working Group of the
International Lymphoma Epidemiology Consortium
(InterLymph) in 2007,14 which was recently updated tak-
ing into account the revisions of the WHO classification.15
The InterLymph and HAEMACARE schemes are compa-
rable except that the InterLymph classification regards the
obsolete Working Formulation3 category of malignant
lymphoma, mixed small and large cell, diffuse (code 9675)
as not otherwise specified (NOS), whereas in the
HAEMACARE grouping strategy this category is grouped
as diffuse large B-cell lymphoma.
In the present study we estimated 5-year relative sur-
vival rates for patients with lymphoid neoplasms diag-
nosed in Europe in 2000-2002, according to the groups
defined by HAEMACARE, and compared survival across
European regions according to age and sex.
Design and Methods
Cancer registries
Data on lymphoid neoplasms from 48 cancer registries oper-
ating in 20 countries and participating in EUROCARE-4 were
considered for inclusion in the analysis.16 The registries were
grouped into five regions: Northern Europe (Iceland, Norway
and Sweden); UK and Ireland (England, Ireland, Northern
Ireland, Scotland, and Wales), Central Europe (Austria, France,
Germany, Switzerland and The Netherlands); Southern Europe
(Italy, Malta, Slovenia, and Spain); and Eastern Europe (Czech
Republic, Poland, and Slovakia). Eleven of the cancer registries
are national registries, the others cover variable percentages of
their respective national populations. The number of cases con-
tributed by each registry is shown in Table 1, together with indi-
cators of data quality.
The cancer registries provided data on lymphoid neoplasms
diagnosed in 1995-2002; for most cases follow-up was only avail-
able to 2003. We estimated 5-year relative survival for cases diag-
nosed in 2000-2002. Since most of these cases did not have 5 years
of follow-up, we used the period method17 to estimate survival:
with this method, survival over the years for which follow-up data
were unavailable was estimated from the survival experience of
patients diagnosed in recent time periods. 
To obtain a set of cases with adequately specified morphology,
we excluded cancer registries in which NOS morphology consti-
tuted over 30% of cases. The ICD-O-3 NOS codes are: lymphoma
9590, NHL 9591, and lymphatic leukemia 9820 and 9832. The can-
cer registries of Sweden, Northern Ireland, Austria, Friuli Venezia-
Giulia (Italy), Reggio Emilia (Italy), Umbria (Italy), and Cracow
(Poland) were excluded for this reason. The resulting study popu-
lation, from the remaining 41 cancer registries, consisted of
138,581 cases. 
HAEMACARE categories of lymphoid neoplasms
HAEMACARE grouped lymphoid neoplasm morphological
entities (defined by ICD-O-3 codes) into six major categories:18
Hodgkin’s lymphoma (HL), mature B-cell neoplasms, mature T-
cell and natural killer cell neoplasms (T-NK), precursor cell neo-
plasms, composite Hodgkin’s and non-Hodgkin’s lymphoma, and
unknown type lymphoid neoplasm (NOS). Each of these cate-
gories was further divided into sub-categories of similar cell line-
age and prognosis (Table 2). There were very few cases of com-
posite Hodgkin’s and non-Hodgkin’s lymphoma (29 cases) and B-
cell prolymphocytic leukemia (14 cases); for completeness and to
comply with WHO indications, we present data for these entities,
but do not include them in the survival analyses. 
Statistical analysis 
Five-year relative survival, by HAEMACARE groups, was esti-
mated overall and for each European region for patients diag-
nosed in 2000-2002, using the period approach.17 Survival was
also estimated by sex and age. We present relative survival rates
in accordance with standard practice for comparative popula-
tion-based cancer-survival analyses.19,20 Relative survival was
estimated as the ratio of the observed survival of patients with
cancer to the expected survival of a group of people of the cor-
responding sex and age in the general population. Expected sur-
vival was based on cancer registry area-specific or country-spe-
cific official mortality data, and was estimated according to
Hakulinen’s method.21 The analyses were carried out using
SEER*Stat software.22
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Table 1. Lymphoid neoplasms diagnosed in 1995-2002 and recorded in 48 European cancer registries, with data quality indicators 
Country/Area Cancer N. of Lost to DCO/ Microscopically Poorly specified
registry cases follow-up autopsy verified (NOS) neoplasms
(%) (%) (%) (%)
Northern Europe 29,716 0.3 1.7 98.8 32.5
ICELAND ICELAND 501 0.0 0.2 99.6 2.4
NORWAY NORWAY 9,752 0.4 1.5 96.5 18.4
SWEDEN SWEDEN* 19,463 0.2 1.8 99.9 40.3
UK and Ireland 66,322 0.0 2.8 87.7 24.3
IRELAND IRELAND 7,271 0.0 2.1 95.8 24.2
UK England East Anglia 6,716 0.3 1.7 85.4 24.0
Northern & Yorkshire 12,715 0.0 0.9 92.5 21.5
Oxford 6,101 0.0 0.6 100.0 20.2
West Midlands 11,199 0.0 6.1 84.0 27.3
UK  Northern Ireland NORTHERN IRELAND* 3,545 0.0 1.7 81.9 37.5
UK Scotland SCOTLAND 11,981 0.0 0.7 94.1 22.2
UK Wales WALES 6,794 0.0 9.4 58.6 25.8
Central Europe 33,910 0.3 5.3 93.4 19.5
AUSTRIA AUSTRIA* 13,775 0.0 11.2 86.8 37.6
France Cote d’Or Haemat. 1,278 0.0 0.0 100.0 3.4
Germany Saarland 2,276 0.0 3.7 94.2 5.3
Switzerland Basel 793 1.5 1.9 98.6 11.7
Geneva 902 4.0 0.4 97.0 17.9
St. Gallen 1,044 1.1 1.2 98.5 6.6
Ticino 791 2.5 3.3 94.4 9.1
The Netherlands Amsterdam IKN 5,631 0.1 0.5 98.8 4.2
Eindhoven IKZ 1,524 0.0 0.0 97.3 11.8
North Netherlands 3,704 0.0 1.8 98.4 7.9
Twente 2,192 0.6 0.8 98.5 8.1
Southern Europe 41,222 0.8 1.2 93.0 20.2
Italy Alto Adige 1,107 0.0 0.2 98.5 11.4
Biella 681 0.2 1.2 93.1 5.6
Ferrara 1,252 0.8 1.7 97.0 9.3
Firenze 3,672 0.1 0.7 74.9 22.1
Friuli V.G.* 4,049 0.9 1.6 99.4 37.1
Genova 2,449 0.0 1.0 86.2 8.3
Modena 2,139 1.8 0.3 99.5 5.4
Napoli 579 5.0 1.0 86.5 22.1
Parma 1,513 0.6 0.0 99.7 19.7
Ragusa 598 0.0 1.2 89.8 13.0
Reggio Emilia* 1,337 0.1 0.1 95.7 57.4
Romagna 3,594 0.3 2.2 97.5 10.9
Salerno 1,823 8.0 1.3 95.6 26.0
Sassari 1,154 0.0 0.2 95.5 5.9
Torino 2,373 0.1 1.6 94.1 17.3
Trento 819 0.4 0.5 97.4 13.1
Umbria* 2,436 0.9 0.7 79.9 42.9
Veneto 4,652 0.6 1.5 93.1 23.6
MALTA MALTA 701 0.0 0.7 95.4 17.3
SLOVENIA SLOVENIA 3,049 0.1 1.4 99.6 11.8
Spain Girona 1,245 0.1 2.3 97.3 4.8
Eastern Europe 12,996 0.2 6.8 91.9 20.0
Czech Republic West Bohemia 1,571 0.7 7.4 92.9 13.0
Poland Cracow* 980 1.7 4.1 87.8 41.8
Kielce 1,748 0.0 0.0 89.8 29.1
Warsaw 2,195 0.1 1.4 92.0 24.3
SLOVAKIA SLOVAKIA 6,502 0.0 10.7 92.8 14.5
EUROCARE pool 184,166 0.3 3.0 92.0 23.5
*Data from cancer registries with more than 30% of NOS cases are not included in the survival analyses. Cancer registries in upper case cover entire national populations.
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Table 2. Total number  of  lymphoid neoplasms diagnosed in 1995-2002 and archived by 41 European cancer registries, divided by HAEMACARE
group, together with mean number of cases used to estimate survival, and period estimates for 2000-2002 of 5-year relative survival.
HAEMACARE grouping ICD-O-3 ICD-O-3 description N. of cases Mean N. Overall 5-year
morphology 1995-2002 of cases2 period survival 
Code (95%CI)
Hodgkin’s lymphoma, total 12,405 4,730 84.5 (83.2-85.7)
Hodgkin’s lymphoma, 9659 Hodgkin’s lymphoma, nodular lymphocyte predominant 360 137.5 95.8 (91.4-100.0)
nodular lymphocyte predominant 
Classical Hodgkin’s lymphoma 12,045 4,563.5 84.0 (82.8-85.3)
9650 Hodgkin’s lymphoma, NOS1
9661 Hodgkin’s granuloma [obsolete] 2,025 709.0 73.6 (69.7-77.5)
9662 Hodgkin’s sarcoma [obsolete] 
9651 Hodgkin’s lymphoma, lymphocyte rich 576 204.5 93.1 (88.3-97.8)
9663 Hodgkin’s lymphoma, nodular sclerosis (NOS1)
9664 Hodgkin’s lymphoma, nodular sclerosis cellular phase 7,054 2,710.0 87.8 (86.3-89.2)
9665 Hodgkin’s lymphoma, nodular sclerosis, grade 1
9667 Hodgkin’s lymphoma, nodular sclerosis grade 2
9652 Hodgkin’s lymphoma, mixed cellularity, NOS1 2,164 813.5 78.9 (75.5-82.3)
9653 Hodgkin’s lymphoma, lymphocyte depletion, (NOS1)
9654 Hodgkin’s lymphoma, lymphocyte depletion,  diffuse fibrosis 226 75.0 54.4 (40.5-68.3)
9655 Hodgkin’s lymphoma, lymphocyte depletion, reticular
Mature B-cell neoplasms 89,556 33,907 53.9 (53.2-54.5)
Chronic lymphocytic leukemia/small 9670 Malignant lymphoma, small B-cell lymphocytic, NOS1 22,871 8487.5 69.1 (67.7-70.5)
lymphocytic lymphoma 9823 B-cell chronic lymphocytic leukemia 
Immunoproliferative diseases 9671 Malignant lymphoma, lymphoplasmacytic
9760 Immunoproliferative disease, NOS1 4,128 1531.5 66.2 (63.0-69.4)
9761 Waldenström’s macroglobulinemia
9762 Heavy chain disease 
Mantle cell lymphoma 9673 Mantle cell lymphoma 2,055 789.0 43.8 (39.7-47.8)
Follicular lymphoma 9690 Follicular lymphoma, NOS1 9,392 3635.5 72.8 (71.0-74.6)
9691 Follicular lymphoma, grade 2
9695 Follicular lymphoma, grade 1
9698 Follicular lymphoma, grade 3
Diffuse large B-cell lymphoma 9675 Malignant lymphoma, mixed small and large cell, diffuse [obsolete]
9678 Primary effusion lymphoma
9679 Mediastinal large B-cell lymphoma 18,685 7164.5 49.3 (47.8-50.6)
9680 Malignant lymphoma, large B-cell, diffuse, NOS1
9684 Malignant lymphoma, B large cell, diffuse, immunoblastic, NOS1
Burkitt’s lymphoma 9687 Burkitt’s lymphoma, NOS1 949 369.5 56.0 (50.7-61.2)
9826 Burkitt cell leukemia
Marginal zone lymphoma 9689 Splenic marginal zone B-cell lymphoma
9699 Marginal zone B-cell lymphoma, NOS1 (MALT lymphoma)3 1,995 797.5 81.4 (77.7-85.2)
9764 Immunoproliferative small intestinal disease (Mediterranean lymphoma)
B-cell prolymphocytic leukemia 9833 Prolymphocytic leukemia, B-cell type 14 - -
Hairy cell leukemia 9940 Hairy cell leukemia 1,403 527.5 93.9 (90.1-97.7)
Plasma cell neoplasms 28,064 10299.5 32.6 (31.5-33.7)
9732 Multiple myeloma 25,721
9733 Plasma cell leukemia 163
9731, 9734 Plasmacytoma NOS1, plasmacytoma, extramedullary 2,180
Mature T-cell and NK-cell neoplasms 5,149 2,051 60.1 (57.6-62.7)
T lymphoma cutaneous 9700 Mycosis fungoides
9701 Sézary’s syndrome
9709 Cutaneous T-cell lymphoma, NOS1 2,620 1,046.5 83.4 (80.0-86.7)
9718 Primary cutaneous CD30+ T cell-lymphoproliferative  disorder
9708 Subcutaneous T panniculitis-like T-cell lymphoma   
continued on the next page
Results
Table 1 shows the total number of cases, divided by reg-
istry and by European region, with quality indicators. The
quality indicators are percentages of cases lost to follow-
up, cases determined by death certificate only or notified
autopsy (DCO/autopsy), cases microscopically confirmed,
and cases with NOS morphology. 
Overall, 0.3% of cases were lost to follow-up, with the
highest figures in Southern Europe (0.8%; range, 0.0-
8.0%). Overall 3.0% of cases were DCO/autopsy, with
highest proportions in Central Europe (5.3%; range, 0.0-
11.2%) and Eastern Europe (6.8%; range, 0.0-10.7%). 
Overall, 92.0% of cases were microscopically verified,
although the percentages were lower for UK and Ireland
(87.7%) and particularly low for Wales (58.6%), where a
large proportion of pathology records was not available to
the registry.12 The proportion of NOS cases was similar
across regions (19.5 to 24.3%), but was particularly high in
Northern Europe (32.5%; range, 2.4-40.3%). Considering
individual cancer registries, the proportion of NOS cases
varied more than the other quality indicators, ranging
from 2.4% (Iceland) to 57.4% (Reggio Emilia). 
Survival of patients according to HAEMACARE group
and sex
Table 2 shows, for each ICD-O-3 entity and
HAEMACARE group, the total numbers of cases of lym-
phoid neoplasms diagnosed in 1995-2002, the mean num-
ber of cases contributing to the period estimates of 5-year
relative survival for 2000-2002, and the period estimate of
5-year relative survival with corresponding 95% confi-
dence intervals for 2000-2002.
The 5-year relative survival rate was 57% overall but
varied markedly according to HAEMACARE group.
Relative survival was highest for patients with nodular
lymphocyte predominant Hodgkin’s lymphoma (95.8%),
hairy cell leukemia (93.9%), classical Hodgkin’s lym-
phoma (84.0%) and T cutaneous lymphoma (83.4%). This
last group consisted mainly of patients with mycosis fun-
goides. Survival was lowest for patients with mantle cell
lymphoma (43.8%), other T/NK-cell lymphomas (38.6%),
and plasma cell neoplasms (32.6%).
Figure 1 shows 5-year relative survival by sex and
HAEMACARE group. Overall survival was similar in
males (57.0%) and females (56.7%). Survival was also
similar between the sexes within the individual
HAEMACARE groups, although better survival in females
than males was found for chronic lymphocytic
leukemia/small lymphocytic lymphoma (CLL/SLL).
Survival of  patients in HAEMACARE groups according
to age at diagnosis
Online Supplementary Table S1 shows the distribution of
patients in HAEMACARE groups by age category and
European region. Approximately 80% of all lymphoid
neoplasms occurred in patients over 50 years, and only
3.4% occurred in patients under 14 years. The proportions
of the different subtypes of lymphoid neoplasms also var-
ied markedly with age. Thus 5.2% of HL, 24.2% of
Burkitt’s lymphoma/leukemia (BL) and 52.5% of precur-
sor cell neoplasms occurred in patients under 14 years,
whereas 63.8% of HL, 39.1% of BL and 25.7% of precur-
sor cell neoplasms occurred in the age group from 15-49
years old. Follicular lymphoma (FL) (48.5%), hairy cell
leukemia (HCL) (46.1%) and mantle cell lymphoma
(MCL) (45.6%) were mainly diagnosed in the age group
from 50-69 years old. Over half of the patients with
CLL/SLL, immunoproliferative diseases, plasma cell neo-
plasms, and B-cell prolymphocytic leukemia were 70
years or older. The proportion of NOS increased substan-
tially with age, from 1.4% in children under 14 to 47.9%
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Other T  and NK- cell lymphomas 9702 Mature T-cell lymphoma, NOS1
9705 Angioimmunoblastic T cell lymphoma
9714 Anaplastic large cell lymphoma, T-cell and null cell type 2,529 987.5 38.6 (35.2-41.9)
9716 Hepatosplenic gamma delta cell lymphoma 
9717 Intestinal T-cell lymphoma
9948 Aggressive NK-cell leukemia
9719 NK/T cell lymphoma, nasal and nasal type,
9827 Adult T-cell leukemia/lymphoma (HTLV-1 positive)
9831 T-cell large granular lymphocytic leukaemia 
9834 Prolymphocytic leukemia, T-cell type
Precursor cell neoplasms
9728, 9836 Precursor B- cell lymphoblastic lymphoma/leukemia 257
9729, 9837 Precursor T-cell lymphoblastic lymphoma/leukemia 118
9727, 9835 Precursor cell lymphoblastic lymphoma/leukemia NOS1 5,831
Composite Hodgkin’s and 9596 Composite Hodgkin’s and non-Hodgkin’s lymphoma 29 -
non-Hodgkin’s lymphoma
Unknown type lymphoid neoplasm, total 25,236 8,720 48.2 (46.9-49.6)
Lymphoma, NOS1 9590 Malignant lymphoma, NOS1 9,149 3,097 42.1 (39.9-44.4)
Non-Hodgkin’s lymphoma, NOS1 9591 Malignant lymphoma, non-Hodgkin’s, NOS1 15,285 5383 51.8 (50.1-53.5)
Lymphatic leukemia, NOS1 9820, 9832 Lymphoid leukaemia, NOS1, prolymphocytic leukemia, NOS1 802 240 39.3 (31.6-47.1)
Lymphoid neoplasms, total 138,581 51,847 56.9 (56.4-57.4)
1NOS: not otherwise specified; 2Mean number of cases contributing to period survival estimates  for 2000-2002; 3Marginal zone B-cell lymphoma, NOS (ICD-O-3 code 9699) includes
both MALT lymphoma and nodal marginal zone lymphoma, if site is not known.
continued from the previous page
in people over 70 years old.
Online Supplementary Figure S1 shows trends in 5-year
relative survival rates for 2000-2002 according to age at
diagnosis. In general survival decreased with advancing
age at diagnosis and fell particularly markedly after the age
of 50. The survival rate for patients with precursor cell
neoplasms fell dramatically from 84.4% in patients under
14 years old, to 8.8% in patients over 70 years old. A sim-
ilarly marked decline with age was also found for classical
HL, BL and NHL NOS. 
Patients with diffuse large B-cell lymphoma (DLBCL)
and other T/NK-cell lymphomas had the worst survival
(74.4% and 72.0%, respectively) in the youngest age cate-
gory, although for both these entities the number of cases
was low, complicating interpretation.
The survival rate of patients with plasma cell neo-
plasms, mainly represented by multiple myeloma, was
significantly higher among patients under 50 years old
(59.0%) than among older patients  (50-69 years, 39.6%;
70-99 years, 21.9%).
Distribution of HAEMACARE groups by region
HL and precursor cell neoplasms formed high propor-
tions of cases in Eastern Europe (Table 2) (13.2% and
6.1%), while mature B-cell and T/NK-cell neoplasms
formed high proportions of all cases in Central Europe
(74.6% and 4.7%) and Southern Europe (67.9% and 4.8%)
(Online Supplementary Table S1). DLBCL formed the high-
est proportion of cases in Central Europe (20.3%), and the
lowest in Eastern Europe (9.6%). Marginal zone lym-
phomas were uncommon in Eastern Europe (0.5%) and
the UK and Ireland (0.5%). MCL accounted for 1.5% of all
lymphoid neoplasms in Europe (range, from 1.2 % in UK
and Ireland to 1.8% in Southern and Central Europe).
Figure 2 shows 5-year relative survival rates divided by
HAEMACARE group and region. For most HAEMACARE
entities, survival was similar across regions, although for
CLL/SLL and immunoproliferative diseases, survival was
significantly lower in Eastern Europe than in other regions. 
Discussion
This study provides a comparative analysis of 5-year rel-
ative survival rates for patients diagnosed with lymphoid
neoplasms in 2000-2002, according to HAEMACARE
group, age and sex, across European regions. To our
knowledge this is the first population-based study on a
large European dataset. It is also novel because it groups
individual lymphoid neoplasm entities (defined by ICD-
O-3 code) into HAEMACARE categories based primarily
on cell lineage and similar prognosis, and is, therefore, use-
ful for clinical and epidemiological studies18,23 Past popula-
tion-based studies divided lymphoid neoplasms into
broad categories (typically NHL versus HL) to investigate
incidence and survival.24 This is unsatisfactory because
survival and incidence vary greatly between ICD-O-3 enti-
ties, complicating comparisons and in particular making it
difficult to interpret regional differences in survival.
A striking finding of the present study is that survival
differences between men and women were small. The
exception was CLL/SLL, for which the survival of affected
women was better than that of men. Previous studies25,26
had found that, among patients with lymphoid neo-
plasms, the survival of males was worse than that of
females.
With regard to the effect of age on survival, we found
that survival decreased with advancing age at diagnosis for
most HAEMACARE groups, as has been well documented
for most types of cancer.27 The markedly lower survival in
the oldest patients (Online Supplementary Figure S1) togeth-
er with the sharp increase in NOS cases with advancing
age (Online Supplementary Table S1) point to a decline in
the quality of diagnostic workup and of care as the age of
the patient increases, suggesting that older patients may
not be receiving optimal treatment for their conditions.
However ‘less insistent’ application of potentially effective
therapies in the elderly could be due to poor toleration of
cytotoxic agents or the frequent presence of comorbidi-
ties. In addition elderly patients are under-represented in
randomized clinical trials,28,29 so evidence-based treatment
guidelines specifically for the elderly are lacking. 
For most lymphoid neoplasms, survival did not vary sig-
nificantly across the five European regions. This finding
suggests a major increase in survival of patients with these
diseases in Eastern European countries compared to earlier
years.30,31 The exceptions were for CLL/SLL and immuno-
proliferative diseases, with survival in Eastern Europe
being significantly lower than in other European regions.
Incomplete registration of CLL/SLL cases with better sur-
Survival of patients with lymphoid neoplasms
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Figure 1. Sex-specific period estimates of 5-year relative survival for
patients with lymphoid neoplasms diagnosed in 2000-2002 and
grouped according to HAEMACARE.
vival may account for the difference: CLL/SLL cases with
a better prognosis are generally diagnosed on an outpa-
tient basis, so reporting sources are usually pathology lab-
oratories and doctors’ offices.32 These cases are more likely
to be unreported than the poorer prognosis cases treated
in (and reported by) hospitals.33,34 This could be particular-
ly true for Eastern European countries, where the relative-
ly low total national expenditure on health compared to
that of other regions35 may have lowered hospital admis-
sions for patients potentially treatable at home. 
We might have expected to see more marked survival
differences between regions for DLBCL and FL in relation
to a heterogeneous introduction of the use of rituximab.
Rituximab is a monoclonal antibody that binds the B-cell
transmembrane protein CD20 resulting in lymphoma cell
lysis. It started to be used in Europe in 2000, but not simul-
taneously in all countries36-38 and significant survival
improvements for DLBCL and FL patients treated with rit-
uximab have been described in a population-based
study.39,40
The treatment of multiple myeloma has also changed
over the last decade with the introduction of thalidomide,
lenalidomide and proteasome inhibitors (bortezomib), as
add-on therapy to conventional cytotoxic and transplanta-
tion regimens.41 We found that the survival of patients
with multiple myeloma was poor at 32.4% and
unchanged compared to the 35% reported for 1995-1999
by EUROCARE-4.24 A US study reported a similar survival
rate (30%) for the same time period.25 By contrast, survival
of patients with multiple myeloma was significantly bet-
ter (59%) in European patients under 50 years old, as also
observed in the USA.42 The US study found a significant
increase in survival for younger patients from 1990-1992
to 2002-2004, but only a moderate improvement for older
patients. Improvements in survival of patients with
DLBCL, FL and multiple myeloma may become evident
after 2004, in relation to more extensive application of the
new treatments. Only longitudinal data from population-
based studies can show whether these treatments lead to
real survival improvements.
The strengths of our study are its large size (≈140,000
cases), European scope, and use of the period method to
estimate 5-year relative survival rates when follow-up was
shorter than 5 years. An important limitation regards data
quality. Overall, around 16% of the cases we analyzed were
NOS and this figure varied considerably with European
region (Online Supplementary Table S1). Non-specification of
the morphology of lymphoid neoplasms results in misclas-
R. Marcos-Gragera et al.
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Figure 2. European region-specific period estimates of 5-year relative survival of patients with lymphoid malignancies diagnosed in 2000-
2002, and grouped according to HAEMACARE.
sification of subtype-specific distribution, and biases the
survival analyses since the majority of NOS cases have poor
prognoses. Erroneous automatic conversion of ICD-O
codes from previous to recent versions could be responsible
for some of the NOS cases.43,44 In addition, the low propor-
tions, in some regions, of entities first recognized in the
2001 WHO classification (e.g marginal zone lymphomas)
suggests that many of these entities were simply classified
as NOS. A central pathology review would have reduced
the number of NOS cases but this is not feasible in popula-
tion-based studies involving tens or hundreds of thousands
of cases. Nevertheless, the relatively high percentage of
NOS cases pinpoints the need to improve the quality of
data on hematologic malignancies archived by cancer reg-
istries. It is noteworthy that the overall percentage of NOS
cases declined from 26% in 1995 to 19.8% in 2002 (data not
presented) so there was an encouraging improvement over
the study period. It is also worth noting that we had a very
few cases of composite HL/NHL (n=29). We suspect that
this may be an artificially low number, perhaps because of
the complexities of the procedures employed by cancer reg-
istries for coding multiple malignancies. Furthermore, com-
posite NHL/NHL cases are not recorded by European can-
cer registries; the coexistence of multiple NHL with the
same immunophenotype (particularly the not uncommon
occurrence of FL with DLBCL) is not accounted for by can-
cer registries. This is certainly related to the fact that there
is no code in the ICD-O-3 for such cases to be registered.
In conclusion, our findings show that survival for most
subtypes of lymphoid neoplasms declined sharply – while
the proportion of NOS cases increased steeply – with age at
diagnosis, suggesting under-treatment in the elderly, while
survival differences between the sexes were small. The
comparison of our overall data with those of previous
analyses suggests a decline in survival differences across
European regions. We emphasize, however, that useful
comparisons of survival of patients with lymphoid neo-
plasms across regions (and over time) require that the indi-
vidual neoplastic entities be grouped into clinically mean-
ingful categories with similar prognoses; the HAEMACARE
groupings used in the present study appear eminently suit-
able for this purpose. The final message of this paper is that
although the quality of cancer registry data on lymphoid
neoplasms needs to be improved and the data integrated
with detailed information (immunophenotype, genetic
abnormalities, molecular data and clinical data) necessary
for classifying these diseases according to the latest WHO
classification,8 the information presently available in cancer
registries represents a good benchmark for further descrip-
tive and analytical studies.
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